GlyH-101 | CAS#328541-79-3 | CFTR inhibitor

MedKoo Cat#: 510335 | Name: GlyH-101

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GlyH-101 is a CFTR inhibitor (cystic fibrosis transmembrane conductance regulator). GlyH-101 is a glycine hydrazide that has been shown to block CFTR channels. GlyH-101 blocked I(Cl.PKA) in a concentration- and voltage-dependent fashion (IC(50) at +100 mV=0.3 Â± 1.5 μM and at -100 mV=5.1 Â± 1.3 μM). GlyH-101 blocks the open pore of cardiac CFTR channels at an electrical distance of 0.15 Â± 0.03 from the external membrane surface.

Chemical Structure

GlyH-101

CAS#328541-79-3

Theoretical Analysis

MedKoo Cat#: 510335

Name: GlyH-101

CAS#: 328541-79-3

Chemical Formula: C19H15Br2N3O3

Exact Mass: 490.9480

Molecular Weight: 493.16

Elemental Analysis: C, 46.27; H, 3.07; Br, 32.41; N, 8.52; O, 9.73

Price and Availability

Size	Price	Availability
50mg	USD 250.00	2 Weeks
100mg	USD 450.00	2 Weeks
200mg	USD 750.00	2 Weeks
500mg	USD 1,650.00	2 Weeks
1g	USD 2,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GlyH101; GlyH 101; GlyH-101; CFTR Inhibitor II

IUPAC/Chemical Name

(E)-N'-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(naphthalen-2-ylamino)acetohydrazide

InChi Key

RMBDLOATEPYBSI-NUGSKGIGSA-N

InChi Code

InChI=1S/C19H15Br2N3O3/c20-15-8-13(18(26)17(21)19(15)27)9-23-24-16(25)10-22-14-6-5-11-3-1-2-4-12(11)7-14/h1-9,22,26-27H,10H2,(H,24,25)/b23-9+

SMILES Code

O=C(N/N=C/C1=C(O)C(Br)=C(O)C(Br)=C1)CNC2=CC3=CC=CC=C3C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

GlyH-101 is a potent CFTR inhibitor.

In vitro activity:

On treatment with GlyH‐101, there appeared to be a redistribution of F‐actin from the periphery (Figure 4b,e). Profile analysis of the images using ImageJ confirmed a loss of cortical rim F‐actin to form cytosolic F‐actin polymers in cells treated with GlyH‐101 at 24 h under both static and shear conditions (Figure 4h). Furthermore, a significant (p < 0.05) increase in F‐actin (Figure 4g) and the occurrence of paracellular gaps (Figure 4e) after 24 h of shear stress was observed in cells treated with GlyH‐101, suggesting the formation of cytosolic stress fibers and cellular retraction, compared to cells treated with GlyH‐101 in static conditions. Reference: Physiol Rep. 2021 Dec;9(23):e15128. https://pubmed.ncbi.nlm.nih.gov/34851051/

In vivo activity:

GlyH-101 also decreased AHR in SPT-deficient mice in vivo. This study identifies the manipulation of sphingolipid synthesis as a novel metabolic therapeutic strategy to alleviate AHR. Reference: Am J Respir Cell Mol Biol. 2020 Nov;63(5):690-698. https://pubmed.ncbi.nlm.nih.gov/32706610/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	60.83
	DMF:PBS (pH 7.2) (1:1)	0.5	1.01
	DMSO	57.6	116.75

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 493.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Causer AJ, Khalaf M, Klein Rot E, Brand K, Smith J, Bailey SJ, Cummings MH, Shepherd AI, Saynor ZL, Shute JK. CFTR limits F-actin formation and promotes morphological alignment with flow in human lung microvascular endothelial cells. Physiol Rep. 2021 Dec;9(23):e15128. doi: 10.14814/phy2.15128. PMID: 34851051; PMCID: PMC8634629. 2. Callaghan PJ, Ferrick B, Rybakovsky E, Thomas S, Mullin JM. Epithelial barrier function properties of the 16HBE14o- human bronchial epithelial cell culture model. Biosci Rep. 2020 Oct 30;40(10):BSR20201532. doi: 10.1042/BSR20201532. PMID: 32985670; PMCID: PMC7569203. 3. Heras AF, Veerappan A, Silver RB, Emala CW, Worgall TS, Perez-Zoghbi J, Worgall S. Increasing Sphingolipid Synthesis Alleviates Airway Hyperreactivity. Am J Respir Cell Mol Biol. 2020 Nov;63(5):690-698. doi: 10.1165/rcmb.2020-0194OC. PMID: 32706610; PMCID: PMC7605160.

In vitro protocol:

In vivo protocol:

1. Heras AF, Veerappan A, Silver RB, Emala CW, Worgall TS, Perez-Zoghbi J, Worgall S. Increasing Sphingolipid Synthesis Alleviates Airway Hyperreactivity. Am J Respir Cell Mol Biol. 2020 Nov;63(5):690-698. doi: 10.1165/rcmb.2020-0194OC. PMID: 32706610; PMCID: PMC7605160.

1: Melis N, Tauc M, Cougnon M, Bendahhou S, Giuliano S, Rubera I, Duranton C. Revisiting CFTR inhibition: a comparative study of CFTRinh -172 and GlyH-101 inhibitors. Br J Pharmacol. 2014 Aug;171(15):3716-27. doi: 10.1111/bph.12726. PubMed PMID: 24758416; PubMed Central PMCID: PMC4128068. 2: Norimatsu Y, Ivetac A, Alexander C, O'Donnell N, Frye L, Sansom MS, Dawson DC. Locating a plausible binding site for an open-channel blocker, GlyH-101, in the pore of the cystic fibrosis transmembrane conductance regulator. Mol Pharmacol. 2012 Dec;82(6):1042-55. doi: 10.1124/mol.112.080267. Epub 2012 Aug 24. PubMed PMID: 22923500; PubMed Central PMCID: PMC3502623. 3: Sheppard DN. CFTR channel pharmacology: insight from a flock of clones. Focus on "Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101". Am J Physiol Cell Physiol. 2012 Jan 1;302(1):C24-6. doi: 10.1152/ajpcell.00376.2011. Epub 2011 Oct 12. PubMed PMID: 21998142. 4: Stahl M, Stahl K, Brubacher MB, Forrest JN Jr. Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101. Am J Physiol Cell Physiol. 2012 Jan 1;302(1):C67-76. doi: 10.1152/ajpcell.00225.2011. Epub 2011 Sep 21. PubMed PMID: 21940661; PubMed Central PMCID: PMC3328903. 5: Barman PP, Choisy SC, Gadeberg HC, Hancox JC, James AF. Cardiac ion channel current modulation by the CFTR inhibitor GlyH-101. Biochem Biophys Res Commun. 2011 Apr 29;408(1):12-7. doi: 10.1016/j.bbrc.2011.03.089. Epub 2011 Mar 31. PubMed PMID: 21439936. 6: Kelly M, Trudel S, Brouillard F, Bouillaud F, Colas J, Nguyen-Khoa T, Ollero M, Edelman A, Fritsch J. Cystic fibrosis transmembrane regulator inhibitors CFTR(inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. J Pharmacol Exp Ther. 2010 Apr;333(1):60-9. doi: 10.1124/jpet.109.162032. Epub 2010 Jan 5. PubMed PMID: 20051483.